-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-513723-16-00
4
2021-10-21
metastatic colorectal cancer
-
2024-515273-10-00
7
2021-10-19
Relapsed or refractory Multiple Myeloma (r/r MM)
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2023-507689-26-00
5
2019-10-07
Histologically or cytologically confirmed Locoregional Hepatocellular
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2025-522598-12-00
10
2025-12-17
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
2023-503539-16-00
5
2025-11-11
Non-small Cell Lung Cancer (NSCLC)
-
2024-520407-27-00
5
2025-10-23
X-Linked Protoporphyria (XLP)
-
2024-520050-38-00
5
2025-09-18
Extensive stage small cell lung cancer (ES-SCLC). S
-
2024-515494-95-00
4
2025-05-26
Moderate to Severe Atopic Dermatitis (AD)
-
2024-512946-41-00
5
2025-03-05
Menstrual Migraine
-
2024-511881-35-00
5
2024-12-17
Prurigo Nodularis
-
2024-511304-16-00
4
2024-10-10
Newly Diagnosed Advanced Stage Follicular Lymphoma
-
2024-515936-62-00
9
2024-10-10
Patients with advanced or metastatic gastrointestinal (GI) tumors.
-
2024-516212-24-00
4
2024-10-08
Chronic Myeloid Leukemia
-
2023-504753-12-00
5
2024-10-01
Lung Cancer, Non-Small Cell
-
2023-503923-24-00
5
2024-07-22
Sjögren’s Syndrome With Moderate-toSevere Symptom State